Luis Enrique Hernández González

Dr. Luis Enrique Hernández González

University of Guadalajara, Guadalajara, Jalisco, Mexico

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in Genes
Verified
Journal Article
Open access
PDF file
JAJorge Hermilo Vega Avalos
Jorge Hermilo Vega Avalos
LGLuis Enrique Hernández González
Luis Enrique Hernández González
LZLaura Yareni Zuñiga
Laura Yareni Zuñiga
MPMaria Guadalupe Sanchez Parada
Maria Guadalupe Sanchez Parada
AGAna Elizabeth Gonzalez-Santiago
Ana Elizabeth Gonzalez-Santiago
Raúl Cuauhtémoc Baptista RosasRaúl Cuauhtémoc Baptista Rosas
Raúl Cuauhtémoc Baptista Rosas
Breast cancer has an important incidence in the worldwide female population. Although alterations in the mitochondrial genome probably play an important role in carcinogenesis, the actual evidence is ambiguous and inconclusive. Our purpose was to explore differences in mitochondrial sequences of cases with breast cancer compared with control samples from different origins. We identified 124 mtDNA sequences associated with breast cancer cases, of which 86 were complete and 38 were partial sequences. Of these 86 complete sequences, 52 belonged to patients with a confirmed diagnosis of breast cancer, and 34 sequences were obtained from healthy mammary tissue of the same patients used as controls. From the mtDNA analysis, two polymorphisms with significant statistical differences were found: m.310del (rs869289246) in 34.6% (27/78) of breast cancer cases and 61.7% (21/34) in the controls; and m.315dup (rs369786048) in 60.2% (47/78) of breast cancer cases and 38.2% (13/34) in the controls. In addition, the variant m.16519T>C (rs3937033) was found in 59% of the control sequences and 52% of the breast cancer sequences with a significant statistical difference. Polymorphic changes are evolutionarily related to the haplogroup H of Indo-European and Euro-Asiatic origins; however, they were found in all non-European breast cancers.

18 August 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
LGLuis Enrique Hernández González
Luis Enrique Hernández González
JAJorge Hermilo Vega Avalos
Jorge Hermilo Vega Avalos
LZLaura Yareni Zuñiga
Laura Yareni Zuñiga
MPMaria Guadalupe Sanchez Parada
Maria Guadalupe Sanchez Parada
AGAna Elizabeth Gonzalez-Santiago
Ana Elizabeth Gonzalez-Santiago
Raúl Cuauhtémoc Baptista RosasRaúl Cuauhtémoc Baptista Rosas
Raúl Cuauhtémoc Baptista Rosas
Breast cancer has an important incidence in the worldwide female population. Although alterations in the mitochondrial genome probably play an important role in carcinogenesis, the actual evidence is ambiguous and inconclusive. The purpose of the present work was to explore mitochondrial sequences of clinical cases with breast cancer from different origins and determine the polymorphisms associated. The search for complete and partial mtDNA sequences obtained from breast cancer patients and controls was performed in NCBI Genbank database. We identified 124 mtDNA sequences associated to breast cancer cases of which 86 were complete and 38 partial sequences. Of these 86 complete sequences, 52 belong to patients with a confirmed diagnosis of breast cancer and 34 sequences were obtained from healthy mammary tissue of the same patients used as controls. From mtDNA analysis, two polymorphisms with significative statistical differences were found in D130 in sequences analyzed: m.310del (rs869289246) in 34.6% (27/78) breast cancer cases and 61.7% (21/34) of controls; and m.315dup (rs369786048) in 60.2% (47/78) of breast cancer cases and 38.2% (13/34) of controls. Also, the variant m.16519T>C (rs3937033) was found in 59% of control sequences and 52% of breast cancer sequences with a significant statistical difference. Polymorphic changes are evolutionarily related to haplogroup H of Indo-European and Euro Asiatic origins, however, were found in all non-European sequences with breast cancer.